EXHIBIT 99.1

                                                                  [CYTOGEN LOGO]

COMPANY CONTACTS:

Advanced Magnetics, Inc.                   Cytogen Corporation
Jerome Goldstein, CEO                      Michael Becker, CEO
 or Lisa Gordon, Investor Relations         or Stacy Shearer, Investor Relations
 (617) 497-2070                             (609) 750-8289

                       ADVANCED MAGNETICS SUBMITS RESPONSE
                    TO FDA APPROVABLE LETTER FOR COMBIDEX(R)

CAMBRIDGE, MA, AND PRINCETON,  N.J., (JUNE 25, 2004) -- Advanced Magnetics, Inc.
(Amex: AVM) and Cytogen Corporation (Nasdaq: CYTO) today announced that Advanced
Magnetics  submitted a response to the approvable  letter received from the U.S.
Food  and  Drug  Administration  (FDA)  for  Combidex(R),   Advanced  Magnetics'
investigational  molecular imaging agent to aid in the non-invasive diagnosis of
metastatic lymph nodes.

In response to the submission, the FDA requested that Advanced Magnetics provide
certain additional  details  underlying the existing  supporting data submitted.
The FDA  subsequently  communicated  that the data Advanced  Magnetics is in the
process of gathering,  once  submitted,  look  encouraging to provide a complete
response to the approvable letter.

"We are pleased by these  positive  steps  forward in the  approval  process for
Combidex,"  stated  Jerome  Goldstein,  Chairman,  President and CEO of Advanced
Magnetics.

Combidex   (ferumoxtran-10)  is  an  investigational   molecular  imaging  agent
consisting  of iron oxide  nanoparticles  for use in  conjunction  with magnetic
resonance  imaging  (MRI)  to aid  in  the  differentiation  of  cancerous  from
non-cancerous lymph nodes. Lymph nodes are frequently the site for metastases of
many different types of cancer,  particularly breast cancer and prostate cancer.
Computed  tomography  (CT) and MRI are the  methods  currently  used for imaging
lymph nodes.  Current  guidelines for imaging lymph nodes are that nodes greater
than 10 mm in size are usually deemed  cancerous  while nodes less than 10 mm in
size are generally presumed normal. CT and MRI cannot distinguish  between lymph
nodes that are enlarged due to the infiltration of cancerous cells as opposed to
inflammation nor can these methods reliably detect disease in nodes that are not
enlarged. Clinical studies have shown that Combidex accumulates in non-cancerous
lymph  node  tissue  which  could  enable  doctors  using  MRI to have  improved
diagnostic  confidence  in  differentiating  between  normal and diseased  lymph
nodes.  Combidex  received an approvable letter from the FDA, subject to certain
conditions, in June of 2000.

ABOUT ADVANCED MAGNETICS

Advanced  Magnetics,  Inc. is the premier  developer of  superparamagnetic  iron
oxide nanoparticles used in pharmaceutical  products.  As a leader in its field,
Advanced Magnetics is dedicated to the development and  commercialization of its
proprietary  nanoparticle  technology for use in  therapeutic  iron compounds to
treat  anemia,  as well as  novel  imaging  agents  to aid in the  diagnosis  of
cardiovascular   disease  and  cancer.   For  more  information  about  Advanced
Magnetics, please visit the company's website at www.advancedmagnetics.com,  the
content of which is not part of this press release.

ABOUT CYTOGEN CORPORATION

Founded in 1980,  Cytogen  Corporation  of  Princeton,  NJ is a  product-driven,
oncology-focused  biopharmaceutical  company that develops and  commercializes a
balanced  portfolio of oncology products that address the unmet medical needs of



patients  and  the  physicians  that  serve  them.   Cytogen   directly  markets
QUADRAMET(TM) (samarium Sm-153 lexidronam injection),  PROSTASCINT(R)  (capromab
pendetide) kit for the  preparation  of Indium In-111  capromab  pendetide,  and
NMP22(R)  BLADDERCHEK(R)  (nuclear  matrix  protein-22)  in the  United  States.
Cytogen  has  exclusive   United   States   marketing   rights  to   COMBIDEX(R)
(ferumoxtran-10),  an investigational molecular imaging agent consisting of iron
oxide  nanoparticles  for use in conjunction with magnetic  resonance imaging to
aid in the differentiation of cancerous from non-cancerous lymph nodes, which is
under  review  by the  U.S.  Food  and  Drug  Administration.  Cytogen  is  also
developing therapeutics targeting  prostate-specific  membrane antigen (PSMA), a
protein  highly  expressed  on the  surface  of  prostate  cancer  cells and the
neovasculature of solid tumors.  Full prescribing  information for the Company's
products is available at www.cytogen.com or by calling 1-800-833-3533.  For more
information, please visit the Company's website at www.cytogen.com, which is not
part of this press release.

For Advanced Magnetics:

This document contains forward-looking  statements.  Any statements contained in
this press  release that do not describe  historical  facts are  forward-looking
statements that involve risks and uncertainties  that could cause actual results
to differ  materially from those discussed in such  forward-looking  statements.
Such risks and uncertainties  include the following:  uncertainties  relating to
Advanced Magnetics' ability to successfully address the comments and concerns of
the FDA contained in the approvable letter for Combidex, including uncertainties
relating to the sufficiency of the additional details to be submitted to the FDA
by Advanced Magnetic;  the timing of FDA actions regarding  Combidex,  including
the  timing  of its  review of the  supporting  data or the  additional  details
submitted  in  relation  thereto;  the outcome of FDA actions in response to the
submission,  including  the  possibility  that  the FDA will  not  consider  the
submission  complete  or that the FDA will  require  additional  information  in
support of the submission;  the possibility  that even if the response is deemed
complete  by the FDA,  the FDA could  respond to this  submission  by issuing an
additional  approvable letter with additional conditions for approval or the FDA
could issue a not approvable  letter;  the ability to resolve final labeling for
Combidex with the FDA;  uncertainties  regarding market  acceptance of Combidex;
uncertainties relating to third-party reimbursements;  uncertainties relating to
Advanced  Magnetics'  ability to  continue  to operate  at  commercial  scale in
compliance with FDA regulations and other applicable manufacturing requirements;
uncertainties  relating  to  patents  and  proprietary  rights  and other  risks
identified in Advanced  Magnetics,  Inc.'s  Securities  and Exchange  Commission
filings.  Advanced Magnetics cautions readers not to place undue reliance on any
forward-looking  statements  which  speak  only as of the date  they  are  made.
Advanced  Magnetics  disclaims any  obligation to publicly  update or revise any
such statements to reflect any change in  expectations or in events,  conditions
or  circumstances  on which any such statements may be based, or that may affect
the  likelihood  that  actual  results  will  differ from those set forth in the
forward-looking statements.

For Cytogen:

This press release  contains  certain  "forward-looking"  statements  within the
meaning of the Private Securities  Litigation Reform Act of 1995 and Section 21E
of the Securities Exchange Act of 1934, as amended.  All statements,  other than
statements of  historical  facts,  included in this press release  regarding our
strategy,  future operations,  financial  position,  future revenues,  projected
costs,  prospects,  plans  and  objectives  of  management  are  forward-looking
statements.  Such  forward-looking  statements  involve  a number  of risks  and
uncertainties  and investors are cautioned not to put any undue  reliance on any
forward-looking  statement.  There are a number of important  factors that could
cause  Cytogen's  results  to differ  materially  from those  indicated  by such
forward-looking  statements.  In particular,  Cytogen's business is subject to a
number of significant risks, which include,  but are not limited to: the risk of
obtaining  the  necessary  regulatory  approvals;  the risk of whether  products
result  from  development  activities;  the  risk of  shifts  in the  regulatory
environment  affecting  sales of Cytogen's  products such as  third-party  payor


reimbursement  issues;  the risk  associated  with  Cytogen's  dependence on its
partners for development of certain projects, as well as other factors expressed
from time to time in Cytogen's periodic filings with the Securities and Exchange
Commission  (the  "SEC").  As a result,  this  press  release  should be read in
conjunction with Cytogen's  periodic  filings with the SEC. The  forward-looking
statements  contained herein are made only as of the date of this press release,
and Cytogen  undertakes no obligation  to publicly  update such  forward-looking
statements to reflect subsequent events or circumstances.

                                       ###